Disodium succinoyl farnesylcysteine is a skincare ingredient designed to quiet inflammatory signals in skin, used against visible aging. One controlled study by its owner found fewer crow's-feet wrinkles than the same gel without it; hydration, texture and radiance improved, but the plain gel improved them too. No harm has been documented, yet safety information is limited to a few short studies, and no independent group has tested it in people. (Full Review)

Protocol

Wrinkle and appearance regimen

1% SFC gel, twice daily

Applied to the face for 12 weeks; the trial regimen of Signum Biosciences

Rosacea regimen

3% SFC gel, twice daily

Applied for 4 weeks; the pilot regimen of Signum Biosciences

Time of day

Morning and evening

As in both trials; morning use sits under sunscreen, evening use can be separated from retinoids

Time to effect

Crow's-feet wrinkles

By week 8

Wrinkle changes appeared by week 8 of the 12-week trial

Texture, hydration and radiance

Weeks 8–12

Texture and hydration at weeks 8 and 12, radiance at week 12; skin treated with the plain gel improved too

Rosacea redness and bumps

4 weeks

Pilot of 10 adults who knew their treatment; no control group

Benefits

Medium: Reduced crow's-feet wrinkles; improved skin texture, hydration and radiance

Low: Skin firmness; reduced rosacea redness and bumps

Speculative: Protection against UV-driven collagen breakdown; calming of irritant and allergic skin inflammation

Contraindications

Known allergy to SFC or to any ingredient in the product

Skin with open wounds, active dermatitis or a recent resurfacing procedure (laser resurfacing, chemical peels, microneedling) at the application site (theoretical)

Pregnant or breastfeeding people (theoretical)

Children (theoretical)

Key Interactions

Topical retinoids (vitamin A derivatives: tretinoin, tazarotene, adapalene): caution (theoretical), additive dryness and redness possible

Exfoliating acids (glycolic acid, salicylic acid) and benzoyl peroxide (over the counter): caution (theoretical), more stinging and redness

Topical corticosteroids (hydrocortisone, clobetasol) and calcineurin inhibitors (tacrolimus, pimecrolimus): monitor (theoretical), overlapping anti-inflammatory action

Prescription rosacea treatments (metronidazole, azelaic acid, ivermectin cream): monitor (theoretical), cumulative irritation from stacked actives

Oral prescription drugs (e.g., atorvastatin, warfarin): no interaction expected (theoretical)

Compatible (theoretical): over-the-counter sunscreens (zinc oxide, avobenzone) and moisturizers, topical niacinamide and other anti-inflammatory cosmetic actives (azelaic acid, centella extract), oral skin supplements (Polypodium leucotomos extract, astaxanthin, collagen peptides), LED light therapy (light-emitting diode panels)

Risk & Side Effects

Speculative: Contact irritation or allergy; unknown skin penetration and long-term safety; dampened local immune defense

Monitoring

Marker	Target	Why
Crow's-feet wrinkle grade	No established target; track change from own baseline	Expected to change
Skin hydration	No established target; track change from own baseline	Expected to change
Facial redness grade	No established target; track change from own baseline	Expected to change (rosacea); safety check (new redness)
Local irritation score	No established target; track new symptoms from own baseline	Safety check: persistent stinging, scaling or swelling stops use

Cadence: Baseline photographs, grading and a 3–5 day forearm patch test; skin check at 1 week for irritation; repeat photographs and grading at 8 and 12 weeks, then every 6 months if use continues

Qualitative Assessment

Skin comfort and absence of stinging or tightness
Perceived smoothness and softness to touch
Visible glow or evenness in natural light
Frequency and duration of redness flares

Disodium Succinoyl Farnesylcysteine for Skin Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment